siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS

Ramesh Akkina, Akhil Banerjea, Jirong Bai, Joseph S Anderson, Ming Jie Li, John Rossi

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Gene therapy strategies for HIV infection require gene transduction of hematopoietic stem cells with effective therapeutic constructs. Here we summarize our studies on anti-HIV ribozymes, RNA decoys and the newly described siRNAs. The therapeutic constructs consisted of an anti-CCR5 ribozyme to down-regulate the HIV-1 cell surface co-receptor and ribozymes targeted to viral mRNAs coding for the tat, rev and env proteins. The RNA decoy targeted rev and the siRNA was directed against a sequence common to rev and tat mRNAs. CD34 hematopoietic progenitor cells were transduced with retroviral or lentiviral vectors containing these constructs. They were differentiated into macrophages in vitro and T cells in vivo in a SCID-hu mouse thymopoiesis model. The transgene-containing macrophages and T cells were found to be phenotypically normal. When challenged in vitro with HIV-1, they showed significant anti-viral resistance. These proof-of-concept studies demonstrated the utility of RNA-based anti-HIV constructs for gene therapy.

Original languageEnglish (US)
Pages (from-to)1997-2005
Number of pages9
JournalAnticancer Research
Volume23
Issue number3 A
StatePublished - May 2003
Externally publishedYes

Fingerprint

Catalytic RNA
Genetic Therapy
Acquired Immunodeficiency Syndrome
Stem Cells
HIV
RNA
Hematopoietic Stem Cells
HIV-1
rev Gene Products
Macrophages
tat Gene Products
env Gene Products
T-Lymphocytes
Messenger RNA
SCID Mice
Cell Surface Receptors
Transgenes
Small Interfering RNA
HIV Infections
Down-Regulation

Keywords

  • HIV gene therapy
  • Lentiviral vectors
  • Ribozymes
  • siRNAs
  • Stem cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Akkina, R., Banerjea, A., Bai, J., Anderson, J. S., Li, M. J., & Rossi, J. (2003). siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Research, 23(3 A), 1997-2005.

siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. / Akkina, Ramesh; Banerjea, Akhil; Bai, Jirong; Anderson, Joseph S; Li, Ming Jie; Rossi, John.

In: Anticancer Research, Vol. 23, No. 3 A, 05.2003, p. 1997-2005.

Research output: Contribution to journalArticle

Akkina, R, Banerjea, A, Bai, J, Anderson, JS, Li, MJ & Rossi, J 2003, 'siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS', Anticancer Research, vol. 23, no. 3 A, pp. 1997-2005.
Akkina, Ramesh ; Banerjea, Akhil ; Bai, Jirong ; Anderson, Joseph S ; Li, Ming Jie ; Rossi, John. / siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. In: Anticancer Research. 2003 ; Vol. 23, No. 3 A. pp. 1997-2005.
@article{5158b8d952cc45239fba509a466d9760,
title = "siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS",
abstract = "Gene therapy strategies for HIV infection require gene transduction of hematopoietic stem cells with effective therapeutic constructs. Here we summarize our studies on anti-HIV ribozymes, RNA decoys and the newly described siRNAs. The therapeutic constructs consisted of an anti-CCR5 ribozyme to down-regulate the HIV-1 cell surface co-receptor and ribozymes targeted to viral mRNAs coding for the tat, rev and env proteins. The RNA decoy targeted rev and the siRNA was directed against a sequence common to rev and tat mRNAs. CD34 hematopoietic progenitor cells were transduced with retroviral or lentiviral vectors containing these constructs. They were differentiated into macrophages in vitro and T cells in vivo in a SCID-hu mouse thymopoiesis model. The transgene-containing macrophages and T cells were found to be phenotypically normal. When challenged in vitro with HIV-1, they showed significant anti-viral resistance. These proof-of-concept studies demonstrated the utility of RNA-based anti-HIV constructs for gene therapy.",
keywords = "HIV gene therapy, Lentiviral vectors, Ribozymes, siRNAs, Stem cells",
author = "Ramesh Akkina and Akhil Banerjea and Jirong Bai and Anderson, {Joseph S} and Li, {Ming Jie} and John Rossi",
year = "2003",
month = "5",
language = "English (US)",
volume = "23",
pages = "1997--2005",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

TY - JOUR

T1 - siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS

AU - Akkina, Ramesh

AU - Banerjea, Akhil

AU - Bai, Jirong

AU - Anderson, Joseph S

AU - Li, Ming Jie

AU - Rossi, John

PY - 2003/5

Y1 - 2003/5

N2 - Gene therapy strategies for HIV infection require gene transduction of hematopoietic stem cells with effective therapeutic constructs. Here we summarize our studies on anti-HIV ribozymes, RNA decoys and the newly described siRNAs. The therapeutic constructs consisted of an anti-CCR5 ribozyme to down-regulate the HIV-1 cell surface co-receptor and ribozymes targeted to viral mRNAs coding for the tat, rev and env proteins. The RNA decoy targeted rev and the siRNA was directed against a sequence common to rev and tat mRNAs. CD34 hematopoietic progenitor cells were transduced with retroviral or lentiviral vectors containing these constructs. They were differentiated into macrophages in vitro and T cells in vivo in a SCID-hu mouse thymopoiesis model. The transgene-containing macrophages and T cells were found to be phenotypically normal. When challenged in vitro with HIV-1, they showed significant anti-viral resistance. These proof-of-concept studies demonstrated the utility of RNA-based anti-HIV constructs for gene therapy.

AB - Gene therapy strategies for HIV infection require gene transduction of hematopoietic stem cells with effective therapeutic constructs. Here we summarize our studies on anti-HIV ribozymes, RNA decoys and the newly described siRNAs. The therapeutic constructs consisted of an anti-CCR5 ribozyme to down-regulate the HIV-1 cell surface co-receptor and ribozymes targeted to viral mRNAs coding for the tat, rev and env proteins. The RNA decoy targeted rev and the siRNA was directed against a sequence common to rev and tat mRNAs. CD34 hematopoietic progenitor cells were transduced with retroviral or lentiviral vectors containing these constructs. They were differentiated into macrophages in vitro and T cells in vivo in a SCID-hu mouse thymopoiesis model. The transgene-containing macrophages and T cells were found to be phenotypically normal. When challenged in vitro with HIV-1, they showed significant anti-viral resistance. These proof-of-concept studies demonstrated the utility of RNA-based anti-HIV constructs for gene therapy.

KW - HIV gene therapy

KW - Lentiviral vectors

KW - Ribozymes

KW - siRNAs

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=0041304776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041304776&partnerID=8YFLogxK

M3 - Article

C2 - 12894572

AN - SCOPUS:0041304776

VL - 23

SP - 1997

EP - 2005

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -